<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for relapsed germ cell tumors: Cisplatin, etoposide, and ifosfamide (VIP)&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for relapsed germ cell tumors: Cisplatin, etoposide, and ifosfamide (VIP)<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for relapsed germ cell tumors: Cisplatin, etoposide, and ifosfamide (VIP)<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 21 days.<br/> <strong>Total cycles:</strong> 4.</td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Cisplatin</td> <td>20 mg/m<sup>2</sup> IV per day</td> <td>Dilute with 250 mL NS* and administer over one hour. Do not administer with aluminum needles or IV sets.</td> <td>Days 1 to 5</td> </tr> <tr> <td>Etoposide<sup>¶</sup></td> <td>75 mg/m<sup>2</sup> IV per day</td> <td>Dilute with 500 mL NS* (concentration &lt;0.4 mg/mL) and administer over one hour.</td> <td>Days 1 to 5</td> </tr> <tr> <td>Ifosfamide<sup>¶</sup></td> <td>1200 mg/m<sup>2</sup> per day IV infusion over a minimum of 30 minutes</td> <td>Dilute with NS, D5W, or sterile water for injection* to a final concentration of 50 mg/mL.</td> <td>Days 1 to 5</td> </tr> <tr> <td>Mesna</td> <td>120 mg/m<sup>2</sup> IV</td> <td>Dilute with NS* and administer via slow IV push prior to day 1 infusion of ifosfamide. Total concentration of mesna should not exceed 20 mg/mL.</td> <td>Day 1</td> </tr> <tr class="divider_bottom"> <td>Mesna<sup>Δ</sup></td> <td>1200 mg/m<sup>2</sup> per day continuous IV infusion</td> <td>Dilute with NS* and administer as continuous infusion over 24 hours.<sup>[2]</sup> Total concentration of mesna should not exceed 20 mg/mL. Can mix with ifosfamide.</td> <td>Days 1 to 5</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Hydration</strong></td> <td colspan="3"> <ul> <li>Induction of diuresis using IV NS minimizes the risk of cisplatin nephrotoxicity and ifosfamide bladder toxicity. At least 2000 mL of NS should be administered at a rate of 100 to 125 mL per hour throughout the five days of treatment and continued for at least two hours after the last doses of cisplatin/ifosfamide.</li> <li>Refer to UpToDate topics on cisplatin nephrotoxicity and hemorrhagic cystitis in cancer patients.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>HIGH (&gt;90% frequency of emesis).</li> <li>Concomitant administration of aprepitant may increase the risk of ifosfamide neurotoxicity; it is avoided at many institutions.</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation.<sup>[3]</sup></li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Primary prophylaxis with G-CSF is administered as a routine component of this regimen.<sup>[1]</sup></li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Dose adjustment for baseline liver or kidney dysfunction</strong></td> <td colspan="3"> <ul> <li>Dose adjustment in the setting of baseline kidney impairment (ie, creatinine &gt;3.0 mg/dL or GFR &lt;50 mL/min) requires a balanced discussion of the goals of treatment and the risks of cisplatin.</li> <li>A lower starting dose of ifosfamide may be needed in patients with pre-existing kidney or liver impairment.</li> <li>Before starting treatment with ifosfamide, it is necessary to exclude or correct any urinary tract obstructions.</li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents; chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents; chemotherapy nephrotoxicity and dose modification in patients with kidney impairment, conventional cytotoxic agents; and hemorrhagic cystitis in cancer patients.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential and platelet count weekly during treatment.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assess liver function tests prior to each treatment cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Cisplatin is associated with significant nephrotoxicity. Ifosfamide is associated with cumulative nephrotoxicity, mostly at a total dose above 60 grams/m<sup>2</sup>.<sup>[4]</sup> Clinical manifestations may include hypophosphatemia, kidney potassium wasting, metabolic acidosis with a normal ion gap, and, rarely, polyuria due to nephrogenic diabetes insipidus. Assess creatinine and electrolytes, including potassium and phosphate, daily during treatment, and prior to each new treatment cycle.</li> <li>Refer to UpToDate topics on ifosfamide nephrotoxicity and cisplatin nephrotoxicity.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Mesna does not prevent hemorrhagic cystitis in all patients.<sup>[2]</sup> Perform urinalysis on a morning specimen of urine daily, on days 1 through 5. Refer to UpToDate topic on "Hemorrhagic cystitis in cancer patients".</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for ifosfamide-related neurotoxicity (confusion, coma, rarely seizures, weakness, neuropathy, ataxia, cranial nerve dysfunction) daily, on days 1 through 5. CNS side effects may be especially problematic for those over age 60.</li> <li>Refer to UpToDate topics on overview of neurologic complications of conventional non-platinum cancer chemotherapy.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor vital signs during etoposide infusion.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li>Unless clinically essential, a repeat course of therapy should not be started with a WBC count below 2000/μL and/or a platelet count below 50,000/μL.<sup>[4]</sup></li> <li>Reduce doses of etoposide and ifosfamide each by 25% for subsequent cycles for granulocytopenic fever or thrombocytopenic bleeding with the previous course of therapy.<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Neurotoxicity</strong></td> <td colspan="3"> <ul> <li>Neuropathy usually is seen after cumulative doses of cisplatin beyond 400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment.<sup>[3]</sup></li> <li>Discontinue ifosfamide treatment for encephalopathy.</li> <li>Refer to UpToDate topics on overview of neurologic complications of conventional non-platinum cancer chemotherapy and overview of neurologic complications of platinum-based chemotherapy.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Nephrotoxicity and urotoxicity</strong></td> <td colspan="3"> <ul> <li>It is recommended that subsequent doses of cisplatin be withheld until the serum creatinine is &lt;3.0 mg/dL.</li> <li>If microscopic hematuria (greater than 10 RBCs per high-power field) is present during therapy, then subsequent administration of ifosfamide should be withheld until complete resolution.</li> <li>Refer to UpToDate topics on cisplatin nephrotoxicity and hemorrhagic cystitis in cancer patients.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes"><p>CBC: complete blood count; CNS: central nervous system; GFR: glomerular filtration rate; G-CSF: granulocyte-colony stimulating factors; IV: intravenous; NS: normal saline; RBC: red blood cell; WBC: white blood cell.</p><p><br/>
* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br/>
¶ The initial protocol included empiric reduction of etoposide and ifosfamide doses by 25% for patients who have received prior radiation therapy.<sup>[1]</sup><br/>
Δ Due to a longer half-life of ifosfamide and associated metabolites at higher doses, some references recommend continuation of mesna for 12 to 24 hours beyond completion of ifosfamide to reduce the risk of hemorrhagic cystitis.<sup>[2]</sup></p></div><div class="graphic_reference">References:
<ol>
<li>Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; 16:1287.</li>
<li>MESNA injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed September 19, 2019).</li>
<li>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on September 19, 2019).</li>
<li>Ifosfamide injection, powder, for solution . United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on September 19, 2019).</li>
</ol></div><div id="graphicVersion">Graphic 51451 Version 23.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
